Semaglutide Weight Loss Dosage Chart: A Complete Titration Guide

Few drugs in modern medicine have accumulated clinical evidence as rapidly as semaglutide, the GLP-1 receptor agonist that has redefined what weight loss pharmacotherapy can achieve. Yet the drug's success is not simply a matter of taking a weekly injection and waiting. The titration schedule, that carefully engineered step-up in dose over months, is as integral to the therapy as the molecule itself. Get the dosage progression right and most patients tolerate the treatment well and reach meaningful fat loss. Rush it, and the side-effect profile becomes the story. This guide presents a complete semaglutide weight loss dosage chart, explains the pharmacological logic behind each escalation step, and covers injection timing, missed-dose management, and the clinical variables that shape an individual patient's protocol.

The titration schedule is as integral to semaglutide therapy as the molecule itself. The dose is not just a number — it is a biological negotiation.

What Semaglutide Is and Why Dose Matters

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a synthetic analogue of a gut-derived hormone that the small intestine releases in response to eating. Natural GLP-1 has a plasma half-life of about two minutes before enzymes called dipeptidyl peptidases break it down. Semaglutide's half-life is approximately seven days, achieved through a fatty acid chain that binds it to albumin in the bloodstream and shields it from enzymatic degradation [1]. That long half-life is what enables once-weekly dosing.

At the cellular level, semaglutide binds GLP-1 receptors distributed across the pancreas, gut, cardiovascular system, and crucially, the hypothalamus and brainstem. In the brain, receptor activation modulates appetite circuits in the arcuate nucleus, suppressing the expression of hunger-promoting neuropeptide Y and agouti-related protein while amplifying satiety signaling. The result is a dose-dependent reduction in caloric intake that goes well beyond simple nausea. Patients consistently report reduced food preoccupation, smaller comfortable portion sizes, and diminished cravings for hyperpalatable foods [2]. This central effect is why dosage titration matters: as the dose rises, central GLP-1 receptor occupancy increases, and so does efficacy — but so does the demand on the gut to adapt to delayed gastric emptying and altered motility.

The peripheral effects are equally important for the metabolic picture. Semaglutide stimulates glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying, collectively blunting postprandial glucose spikes. In individuals with obesity, this translates to improved insulin sensitivity independent of weight loss, though the two effects compound each other substantially [2]. The dose, therefore, is not just a number controlling how much drug circulates. It is a biological negotiation between receptor saturation, central appetite suppression, peripheral metabolic effects, and gastrointestinal tolerability.

The Approved Formulations and Their Starting Points

Two semaglutide formulations are approved specifically for chronic weight management in adults: subcutaneous injectable semaglutide 2.4 mg weekly (branded Wegovy) and oral semaglutide 50 mg daily (branded Rybelsus in its lower doses, and Wegovy oral). The injectable form was the first approved for obesity in June 2021 [2], and it remains the most extensively studied. The oral formulation at the 50 mg dose received FDA approval for weight management in 2024 based on data from the OASIS 1 trial [3]. Both routes share the same active molecule but differ meaningfully in their bioavailability, titration schedules, and practical considerations for patients.

Subcutaneous semaglutide achieves bioavailability approaching 89%, making the dose delivered to systemic circulation highly predictable [1]. Oral semaglutide's bioavailability is considerably lower and more variable, approximately 1% under optimal conditions, which is why the oral dose is expressed in milligrams an order of magnitude higher than the injectable. Absorption of the oral tablet requires ingestion with no more than 120 mL of plain water, at least 30 minutes before the first food, drink, or other medication of the day. Even brief deviations from these instructions meaningfully reduce absorption [3]. This detail matters practically: the dosage chart looks different depending on the route of administration, and the two should never be conflated.

Healthspan's GLP-1 Longevity Care program offers clinically supervised semaglutide protocols across both formulations, with individualized titration plans built around each patient's metabolic baseline, comorbidities, and tolerability history. For those seeking the branded injectable pen specifically, Healthspan also offers the Wegovy Pen with Ongoing Care and, for those preferring the oral route, the Wegovy Pill with Ongoing Care.

Semaglutide Weight Loss Dosage Chart: Injectable (Subcutaneous) Titration

The FDA-approved titration schedule for subcutaneous semaglutide 2.4 mg (Wegovy) is structured across five dose levels, each lasting four weeks before escalation to the next. The schedule is designed to allow GLP-1 receptors in the gut and brainstem to accommodate progressively higher receptor occupancy, minimizing nausea, vomiting, and constipation that are most severe when dose increases are abrupt.

The standard injectable titration schedule is as follows. During weeks 1 through 4, patients inject 0.25 mg subcutaneously once weekly. This is a subtherapeutic dose with minimal weight loss effect on its own; its purpose is entirely tolerability. From weeks 5 through 8, the dose advances to 0.5 mg weekly. Weeks 9 through 12 bring the next escalation to 1.0 mg weekly, at which point patients typically begin to experience measurable appetite suppression and early weight reduction. Weeks 13 through 16 advance the dose to 1.7 mg weekly. Finally, from week 17 onward, patients reach the maintenance dose of 2.4 mg weekly, which is the dose at which the pivotal STEP 1 trial demonstrated a mean body weight reduction of 14.9% over 68 weeks in adults with obesity [2].

In the STEP 1 trial, adults with obesity treated with semaglutide 2.4 mg weekly lost a mean of 14.9% of body weight over 68 weeks — a magnitude previously achievable only with bariatric surgery.

The 16-week ramp is not arbitrary. Receptor desensitization in the gut occurs gradually, and the enteric nervous system's adaptation to altered gastric motility takes weeks to stabilize. Pushing the dose faster than every four weeks consistently increases the incidence of nausea and vomiting, the most common reasons for early treatment discontinuation. Conversely, patients who tolerate each step well should not remain at a subtherapeutic dose for longer than necessary, as every additional week at 0.25 mg or 0.5 mg is a week without full therapeutic benefit. The four-week intervals represent the clinical consensus balancing these competing demands.

A practical note on dose escalation: the prescribing physician may choose to slow the titration if a patient is experiencing persistent nausea at a given dose level. Remaining at 0.5 mg or 1.0 mg for eight weeks instead of four is a clinically accepted strategy. Some patients also reach their therapeutic goal at 1.7 mg and, in discussion with their clinician, elect to remain at that dose rather than advancing to 2.4 mg, particularly if gastrointestinal side effects remain bothersome. The dosage chart provides a framework, not a rigid protocol immune to individual circumstances.

Semaglutide Weight Loss Dosage Chart: Oral Titration

The titration schedule for oral semaglutide 50 mg (Wegovy oral) follows a similar philosophy of slow escalation but differs in the dose levels used. The OASIS 1 trial protocol, which underpins the approved label, began patients at 3 mg daily for four weeks, escalated to 7 mg daily for four weeks, then to 14 mg daily for four weeks, and finally to 25 mg daily for four weeks before reaching the maintenance dose of 50 mg daily [3].

At the 50 mg daily maintenance dose, OASIS 1 demonstrated a mean body weight reduction of 15.1% over 68 weeks in adults with obesity without type 2 diabetes, nearly identical to the injectable formulation's efficacy at 2.4 mg weekly [3]. This equivalence is clinically significant. For patients who are needle-averse, cannot self-inject reliably, or simply prefer a daily oral pill, the oral formulation now represents a scientifically credible alternative rather than a lesser option. The trade-off is the strict administration requirement: the 30-minute pre-meal window is non-negotiable for adequate absorption, which demands a consistent morning routine.

The oral titration schedule also carries a greater sensitivity to co-administered medications and food. High-fat meals, proton pump inhibitors, and certain pH-altering drugs can all reduce absorption of the oral formulation through their effects on gastric pH and transit time [1]. Patients taking proton pump inhibitors or H2 blockers should discuss this interaction explicitly with their prescriber before beginning oral semaglutide, as the clinical significance is meaningful.

Injection Technique and Timing: What the Label Does Not Always Make Clear

Subcutaneous semaglutide is injected into the abdomen, upper arm, or outer thigh. The injection sites should be rotated each week to prevent lipohypertrophy, the accumulation of fibrous adipose tissue at repeatedly needled sites that can alter drug absorption unpredictably. The Wegovy autoinjector pen is designed to be used by patients without clinical training, but several practical details significantly affect both tolerability and pharmacokinetics.

Temperature matters. Semaglutide pens should be refrigerated between 2°C and 8°C. A pen can be kept at room temperature below 30°C for up to 28 days once in use, but exposure to freezing temperatures or direct sunlight degrades the protein structure and should disqualify the pen from use. Allowing the pen to reach room temperature for 30 minutes before injection meaningfully reduces injection site discomfort, as cold solution increases the sensation of burning during subcutaneous delivery.

Regarding timing, semaglutide's seven-day half-life means it reaches steady-state concentration after approximately five weeks of weekly dosing, regardless of the day of the week chosen. The specific day selected for injection matters less than consistency. Injecting on the same day each week maintains predictable peak and trough concentrations, and in practice, most patients anchor their injection day to a low-stress, easily remembered day such as a Sunday morning. Because gastric emptying is most slowed in the 24 to 48 hours after each injection, some patients find that scheduling the injection on a day when a larger social meal is not anticipated helps manage early-treatment nausea [1].

Injection with or without food makes no meaningful difference to subcutaneous absorption, unlike the oral formulation. The site preparation — clean skin, no alcohol required unless clinically indicated — is standard for any subcutaneous injection. The needle should be inserted at 90 degrees for most patients; those with very low subcutaneous adipose tissue may use a 45-degree angle to avoid inadvertent intramuscular injection, which is not associated with serious harm but may alter absorption kinetics slightly.

Missing a Dose: The Pharmacological Logic of Make-Up Rules

Given semaglutide's seven-day half-life, missing a single weekly injection does not result in abrupt loss of drug effect. Plasma concentrations decline slowly, and a one-week gap does not return the patient to their pre-treatment state. The clinical guidance, however, is specific and worth understanding at a pharmacological level.

If the missed dose is within five days of the scheduled injection, the patient should take the injection as soon as they remember and then resume their regular weekly schedule from that new injection date. If more than five days have passed since the missed dose, the patient should skip the missed dose entirely and administer the next injection on the originally scheduled day. The reason for this distinction is straightforward: administering two injections within two days of each other effectively doubles the delivered dose over a short period, which significantly increases the risk of nausea, vomiting, and hypoglycemia in patients also taking insulin or sulfonylureas [2]. Two injections should never be given in the same 48-hour window.

Extended interruptions of more than four weeks require clinical reassessment. Some patients who interrupt semaglutide therapy for surgical procedures, pregnancy, or supply disruptions experience a return of appetite and weight regain that begins within weeks. The STEP 4 trial's withdrawal arm demonstrated that patients who discontinued semaglutide regained approximately two thirds of their prior weight loss within one year, reinforcing the understanding that obesity is a chronic disease requiring ongoing treatment rather than a curable condition addressed by a finite drug course [4]. Patients resuming after extended interruptions may need to restart from the beginning of the titration schedule or from an intermediate dose, depending on how long therapy was paused and whether significant gastrointestinal sensitivity has returned.

Patients who discontinued semaglutide regained approximately two thirds of their prior weight loss within one year — a finding that reframes obesity as a chronic condition requiring ongoing treatment, not a problem solved by a finite drug course.

Cardiovascular and Metabolic Effects That Extend Beyond Weight

A semaglutide dosage guide focused only on weight loss would miss a substantial portion of the clinical picture. The SELECT trial, published in 2023, enrolled 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes. Patients randomized to semaglutide 2.4 mg weekly experienced a 20% reduction in the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke compared to placebo, over a median follow-up of 34.2 months [5]. This was the first trial to demonstrate cardiovascular mortality benefit from a GLP-1 receptor agonist in a population without diabetes, and it expanded the therapeutic rationale for semaglutide well beyond glycemic control or cosmetic weight reduction.

The mechanisms behind the cardiovascular benefit remain an active area of investigation. Weight loss alone explains part of the effect, as every kilogram of fat lost reduces systemic inflammation, improves endothelial function, and lowers blood pressure. But GLP-1 receptors are also expressed directly on cardiomyocytes and endothelial cells, and animal data suggest direct cardioprotective effects including reduced oxidative stress and improved myocardial glucose utilization, effects that may operate independently of weight [5]. Understanding this extends the scope of who might benefit from semaglutide beyond the conventionally obese patient, a consideration that longevity-focused practitioners are increasingly weighing in clinical context.

Additional metabolic effects documented across the STEP trial program include reductions in HbA1c, systolic blood pressure, triglycerides, C-reactive protein (a marker of systemic inflammation), and hepatic steatosis [2]. These are not secondary findings but core metabolic outcomes that extend the drug's relevance into the broader space of cardiometabolic risk reduction. For patients carrying visceral fat, insulin resistance, and early dysglycemia, each dose escalation step on the titration chart represents not just a step toward a lower number on the scale, but a measurable improvement across the metabolic risk landscape.

Managing Side Effects Across the Titration Curve

Gastrointestinal adverse events are the primary tolerability challenge with semaglutide. In the STEP 1 trial, nausea was reported by 44% of semaglutide-treated patients versus 16% of placebo-treated patients; vomiting occurred in 24% versus 6%; and diarrhea in 30% versus 16% [2]. These rates are substantially higher at the beginning of each new dose level and tend to diminish over two to four weeks as receptor adaptation occurs. Most patients who complete the titration period report that gastrointestinal symptoms become manageable at maintenance doses.

Several practical strategies reduce the impact of nausea during titration. Eating slowly, stopping at the first signal of fullness, avoiding high-fat or highly spiced meals in the days immediately following each dose escalation, and staying well-hydrated all reduce symptom burden. Ginger preparations have modest evidence for nausea reduction in other contexts and are generally safe to use alongside semaglutide. Antiemetic medications such as ondansetron can be prescribed for patients with severe nausea that threatens treatment adherence, though this is a clinical decision to be made with the prescribing physician.

Constipation deserves specific mention because it is sometimes overlooked in favor of nausea as the dominant side effect. Slowed gastric emptying and altered gut motility can reduce stool frequency significantly, and inadequate hydration compounds this effect. Increasing dietary fibre, maintaining fluid intake above two litres per day, and, when necessary, using osmotic laxatives such as polyethylene glycol are the standard management approaches. Laxative use during semaglutide therapy is not a sign of treatment failure; it is a recognized and manageable aspect of GLP-1 pharmacology.

Rare but serious adverse events warrant clinical awareness. Acute pancreatitis has been reported with GLP-1 receptor agonists, and while the absolute risk remains low, any patient who develops severe persistent abdominal pain during semaglutide therapy should be evaluated promptly. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, based on observations of thyroid C-cell tumors in rodent models, though the human clinical relevance of this signal remains uncertain [2]. Patients with these risk factors should not be prescribed semaglutide.

Muscle mass preservation is a clinically important consideration that intersects with dosage. Significant rapid weight loss, regardless of mechanism, tends to include loss of lean mass alongside fat. In the STEP 1 trial, approximately 40% of weight lost by semaglutide-treated patients was lean mass, a proportion similar to diet-alone interventions but concerning for long-term metabolic and functional health [2]. Resistance exercise and adequate protein intake, typically 1.2 to 1.6 grams per kilogram of body weight per day, are the evidence-based strategies for preserving lean mass during GLP-1 therapy. The Alpha-Lactalbumin Protein supplement can support this protein target for patients who find it difficult to reach adequate intake through food alone during a period of reduced appetite.

The Longevity Lens: Semaglutide Beyond the Scale

Semaglutide's entry into longevity medicine follows logically from the SELECT cardiovascular data, but the conversation extends further. Obesity and insulin resistance are among the most powerful drivers of biological aging, accelerating telomere attrition, promoting chronic low-grade inflammation (sometimes termed inflammaging), and fueling cellular senescence, the state in which cells stop dividing but resist apoptosis and secrete inflammatory signals that damage surrounding tissue [6]. By addressing the metabolic underpinnings of these processes, semaglutide may do more than extend healthy years in patients with overt cardiovascular risk; it may modulate the biological aging process itself.

Emerging data from preclinical models and observational studies suggest that GLP-1 receptor signaling influences neuroinflammation, with potential implications for neurodegenerative disease. A 2024 randomized trial reported that semaglutide treatment was associated with a 43% lower risk of a first Parkinson's disease diagnosis over a 5.2-year period in a population of patients with type 2 diabetes [7]. The mechanism posited involves GLP-1 receptor-mediated reduction of alpha-synuclein aggregation and neuroinflammation in dopaminergic neurons, though this remains an area of active investigation rather than established science. Similarly, epidemiological data suggest associations between GLP-1 therapy and reduced dementia incidence, plausibly mediated through improved cerebrovascular health and reduced neuroinflammation [7].

These findings do not yet translate into a recommendation to prescribe semaglutide for neuroprotection in the absence of metabolic indications. But they reframe the clinical significance of each step on the titration chart. The patient progressing from 0.25 mg to 0.5 mg to 1.0 mg is not merely chasing a dress size or a lower HbA1c. Each escalation step moves them further along a biological gradient that may be consequential for cardiovascular, neurological, and metabolic aging simultaneously.

Healthspan's approach to GLP-1 therapy integrates these broader considerations into each patient's protocol, pairing semaglutide with metabolic diagnostics, body composition monitoring, and complementary interventions when appropriate. The CGM Metabolic Protocol provides continuous glucose monitoring data that allow clinicians and patients to observe in real time how semaglutide is reshaping postprandial glucose dynamics at each dose level, offering a granular window into the drug's metabolic effect that no static HbA1c test can provide.

Clinical Variables That Modify the Standard Dosage Chart

The titration schedule described above is a population-level protocol derived from clinical trial populations. Individual patients deviate from it for clinically valid reasons, and understanding those reasons is essential for anyone navigating semaglutide therapy.

Renal and hepatic function do not require dose adjustment for semaglutide, as the drug is primarily cleared through proteolytic degradation rather than renal or hepatic metabolism [1]. This distinguishes semaglutide favorably from many other medications in the metabolic space and simplifies prescribing in patients with chronic kidney disease or nonalcoholic fatty liver disease, two conditions highly prevalent in the target population. However, patients with severe gastrointestinal disease, including diabetic gastroparesis, inflammatory bowel disease in active flare, or a history of gastric surgery, require careful individualized titration given the drug's profound effects on gut motility.

Drug interactions are an underappreciated variable in the semaglutide dosage equation. Because semaglutide slows gastric emptying, it can reduce the absorption rate of orally administered medications that depend on rapid gastric transit. The most clinically relevant example is levothyroxine: patients with hypothyroidism who are stabilized on a specific levothyroxine dose may experience altered absorption and should have their thyroid function rechecked within the first few months of starting semaglutide. Oral contraceptives are another consideration; while no pharmacokinetic interaction has been demonstrated with subcutaneous semaglutide, the oral formulation's absorption characteristics mean it should be taken before, not simultaneously with, any other oral medication [1].

Patients concurrently using insulin or insulin secretagogues such as sulfonylureas face an elevated risk of hypoglycemia as semaglutide amplifies insulin response. The standard clinical approach is to reduce the insulin or sulfonylurea dose proactively when initiating semaglutide, rather than waiting for hypoglycemic episodes to prompt a reactive adjustment. This is a preemptive conversation that should happen before the first injection is administered.

Body weight at baseline influences the absolute milligram dose delivered per kilogram of body weight, which in turn affects both efficacy and tolerability. Patients with severe obesity (BMI above 40) may require the full 2.4 mg maintenance dose to achieve the central GLP-1 receptor occupancy needed for meaningful appetite suppression, while patients closer to the prescribing threshold (BMI 30, or BMI 27 with a weight-related comorbidity) may achieve their treatment goals at an intermediate dose [2]. This is why the titration chart is a starting point and not a final word: the prescribing clinician's job is to titrate to effect within the approved dose range, not to escalate mechanically to the maximum labeled dose regardless of response.

Compounded Semaglutide: What Patients Need to Know

The semaglutide supply shortages of 2022 through 2024 prompted a proliferation of compounded semaglutide products from 503B outsourcing facilities and 503A compounding pharmacies. Compounded versions are not FDA-approved and have not been subject to the same manufacturing controls, stability testing, or bioavailability studies as branded formulations. The FDA has received reports of dosing errors and adverse events associated with compounded semaglutide, in part because some compounded formulations use different concentration expressions that have led to tenfold dosing mistakes [5].

As of early 2025, the FDA declared semaglutide no longer on the shortage list for the injectable formulation, which means compounding under shortage-based exemptions is no longer permitted for 503B facilities. The landscape for compounded semaglutide is evolving rapidly, and patients sourcing compounded products outside of clinically supervised programs should be aware of the regulatory and safety considerations involved. Any semaglutide dosage chart applies specifically to the approved, standardized formulations: the titration schedule, the dose escalation timing, and the missed-dose rules are all calibrated to a product of known concentration and bioavailability.

Long-Term Use and Maintenance: What Happens After the Titration

Reaching the 2.4 mg maintenance dose at week 17 is not the end of the clinical story. The STEP 1 trial ran for 68 weeks, and the weight loss curve continued to progress for most of that period before plateauing in the final months [2]. This plateau reflects the establishment of a new equilibrium between energy intake and expenditure at the suppressed appetite level that semaglutide creates, not loss of drug efficacy. Patients should be counseled that the rate of weight loss will slow as they approach their new biological set point, and that this deceleration is pharmacologically expected, not a treatment failure.

The question of how long to continue semaglutide is one of the most clinically important and underexplored in the current literature. Given the STEP 4 withdrawal data demonstrating rapid weight regain after discontinuation, the working model for most longevity-focused clinicians is that semaglutide, like antihypertensives or statins, is a long-term medication for a chronic condition rather than a short-term intervention [4]. This framing has implications for how patients approach the therapy from the outset: the titration chart is not a countdown to a finish line but the beginning of a maintenance relationship with the drug and the metabolic habits that support it.

Some patients do achieve durable lifestyle changes during the period of appetite suppression that allow them to gradually taper off semaglutide while maintaining a substantial portion of their weight loss. These cases are real but appear to represent a minority. The more common experience is that discontinuation leads to return of appetite, food preoccupation, and weight regain within months. Honest counseling about this probability at the outset of therapy, combined with the development of dietary and exercise habits during treatment, gives patients the best chance of sustaining their healthspan gains whether or not they remain on semaglutide indefinitely.

For patients where semaglutide alone does not achieve sufficient cardiometabolic improvement, combination approaches with other metabolic therapies merit consideration in appropriate clinical contexts. The SGLT2 Protocol and Metformin each address complementary aspects of insulin resistance and glucose metabolism, and their combination with GLP-1 therapy is an area of active clinical and research interest for comprehensive cardiometabolic risk reduction.

Conclusion: The Chart Is the Beginning, Not the Answer

The semaglutide weight loss dosage chart, from 0.25 mg at week one to 2.4 mg at week 17 for the injectable formulation, or from 3 mg to 50 mg over 16 weeks for the oral, is a product of rigorous pharmacokinetic reasoning and clinical trial experience. It represents the scientific community's best understanding of how to introduce a powerful receptor agonist to the body in a way that maximizes benefit and minimizes harm. But it is a framework, not a prescription written in stone. Every patient's gastrointestinal system adapts at its own pace. Every patient's metabolic baseline responds differently. Every patient's life circumstances shape when and how they can realistically adhere to weekly injections or a strict morning oral dosing ritual.

What the dosage chart cannot convey is the broader clinical context in which it sits. The 14.9% mean weight loss in STEP 1 was not achieved by the drug alone; it was achieved by a drug given to motivated participants with access to dietary and behavioral counseling, within a trial that also enrolled many patients who might not represent the full heterogeneity of real-world practice. Understanding this does not diminish semaglutide's remarkable efficacy. It situates it honestly. The drug is a powerful tool. The titration schedule is the method for using that tool safely. And the clinical relationship, built on ongoing monitoring, dose adjustment, and integration with the broader healthspan program, is what translates a pharmacological chart into a lived improvement in health and longevity.